Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure

Keywords

Empagliflozin, Dapagliflozin, Canagliflozin, Medicine, Heart failure

References

• The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐AnalysisBongJoo Jeong, Byoung Kwon Lee, Kap Hwan Kim — 2018
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.A. Michael Lincoff, Kathy Wolski, Stephen J. Nicholls — 2007
• The importance of NLRP3 inflammasome in heart failureBrittany Butts, Rebecca Gary, Sandra B. Dunbar — 2015
• SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaYukihiro Chino, Yoshishige Samukawa, Soichi Sakai — 2014
• Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.Lorraine L. Lipscombe, Tara Gomes, Linda E. Lévesque — 2007
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 TrialJacob A. Udell, Deepak L. Bhatt, Eugene Braunwald — 2014
• Revisiting the links between glycaemia, diabetes and cardiovascular diseaseNaveed Sattar — 2013
• Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus SulfonylureaGuntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock — 2013
• Ketone body β-hydroxybutyrate blocks the NLRP3 inflammasome-mediated inflammatory diseaseYun‐Hee Youm, Kim Nguyen, Ryan W. Grant — 2015
• The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and GlucotoxicityMatthias Oelze, Swenja Kröller‐Schön, Philipp Welschof — 2014
• Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation.Ayan R. Patel, Jeffrey T. Kuvin, Natesa G. Pandian — 2001
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.Steven E. Nissen, Kathy Wolski — 2007
• Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesRobert Ćhilton, I. Tikkanen, Christopher P. Cannon — 2015
• Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology.Joshua M. Hare, Richard J. Johnson — 2003
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.Bernard Zinman, Christoph Wanner, John M. Lachin — 2015
• Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetesHiddo J.L. Heerspink, Dick de Zeeuw, Li Wie — 2013
• Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.Michael A. Weber, Traci A. Mansfield, Valerie A. Cain — 2016
• Role of cell death in the progression of heart failureGordon W. Moe, José Marı́n-Garcı́a — 2016
• The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failureΑlexandros Briasoulis, Emmanuel Androulakis, Theodoros Christophides — 2016
• Inflammation in Heart Failure: The Holy Grail?Jawahar L. Mehta, Naga Venkata K. Pothineni — 2016

Cited by

• Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors.Theodora M. Stougiannou, Konstantinos Christodoulou, Theocharis Koufakis — 2024
• Nocturia and SGLT2 Inhibitors: A Review of Pathophysiology, Clinical Evidence, and Therapeutic ImplicationsMatthew Antonellis, Robert W. Adler, Michael Kozlov — 2025
• O cuidado em saúde baseado em evidênciasBorges, Fernanda da Silveira Sá, Cavalcante, Filipe Paz, Brilhante, Francisco Davi Fernandes — 2023

Related papers

• [ANMCO Position paper: Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in diabetic patients and for the treatment of heart failure patients with and without diabetes].Edoardo Gronda, Claudio Napoli, Massimo Iacoviello — 2021
• Dapagliflozin for heart failure - is it a class effect?Gerard Marshall Raj, Mukta Wyawahare — 2020
• Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of CardiologyPetar Seferović, Gabriele Fragasso, Mark C. Petrie — 2020
• Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fractionMagdy Abdelhamid, Hossam Kandil, Mohamed Hassan — 2022
• SGLT2 inhibition and heart failure—current conceptsJoaquim Silva Custódio, André Rodrigues Durães, Marconi Abreu — 2018
• Sodium-glucose cotransporter type 2 inhibitors: successful running after two haresН. Б. Перепеч, I. E. Mikhailova — 2021
• The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection FractionLindsay A. Brust-Sisti, Nicole Rudawsky, Jimmy Gonzalez — 2022